Jarrod Longcor, MS, MBA, chief business officer, Cellectar Biosciences, Inc., discusses the potential utility of the small-molecule radiotherapeutic phospholipid-drug conjugate CLR 131 in patients with multiple myeloma.

The primary objective of the phase I dose-escalation study (NCT02278315) is to determine the safety and tolerability of CLR 131 in patients with relapsed/refractory disease who have been previously treated with or are intolerant of an immunomodulatory drug and a proteasome inhibitor. Secondary objectives include identifying the recommended phase II dose and schedule and evaluating efficacy.

Patients will receive a fractionated infusion of CLR 131 at increasing doses on day 1 and 7 (±1 day) with concurrent weekly dexamethasone. Preclinical data demonstrated that CLR 131 inhibited tumor growth in mice.

Pending further study, CLR 131 could play a role in patients with triple-class refractory multiple myeloma who have received ≥5 prior lines of therapy, explains Longcor. Due to the design of the agent, the drug could potentially be used in combination with stem cell transplantation or as a bridge to CAR T-cell therapy, concludes Longcor.

Videos

Jarrod Longcor, MS, MBA, discusses the potential utility of the small-molecule radiotherapeutic phospholipid-drug conjugate CLR 131 in patients with multiple myeloma.

Jarrod Longcor, MS, MBA

Articles

The Potential Utility of CLR 131 in Multiple Myeloma